Delcath Systems, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Gerard J. Michel
- Full Time Employees
- 156
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 566 Queensbury Avenue Queensbury NY United States of America 12804
- IPO Date
- May 3, 2018
- CIK
- 0000872912
- Website
- delcath.com
- Similar Companies
- Business
- Delcath Systems, Inc. is an interventional oncology company specializing in the treatment of primary and metastatic liver cancers. The company develops and commercializes proprietary drug and device combination products designed to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure. Its main products include the HEPZATO KIT™ (melphalan for Injection/Hepatic Delivery System), which is FDA-approved for use in the United States, and the CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), which is commercialized in Europe and the United Kingdom. These products are intended for targeted chemotherapy delivery during minimally invasive procedures. Delcath operates primarily in the United States and Europe. Delcath recently reported significant operational progress including the expansion to 25 active U.S. treatment centers and initiation of the global Phase 2 HEPZATO trial focused on liver-dominant metastatic colorectal cancer. They also announced encouraging results from the Phase 2 CHOPIN investigator-initiated trial, showing improved one-year progression-free survival for the combination of CHEMOSAT with immunotherapy agents ipilimumab and nivolumab. The company expects full-year 2025 revenue between $83 million and $85 million, reflecting approximately a 150% increase in treatment volume over 2024. Key strategic highlights include ongoing expansion of treatment centers, strengthening of clinical trial programs, continued adoption of HEPZATO KIT in the U.S., and preparing for broader market penetration with next-generation delivery systems aimed at improving procedural efficiency and standardization. Founded in 1989 and headquartered in New York, Delcath focuses on collaborating with leading oncology treatment centers and academic research institutions such as Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. The company’s core business includes research, development, manufacturing, and distribution of hepatic delivery systems designed to improve outcomes for patients with liver cancers, including metastatic ocular melanoma and colorectal liver metastases. Recent operational developments include renewed supply agreements for melphalan hydrochloride through 2028 and strategic partnerships to support clinical trial and commercial deployment efforts. Delcath thus positions itself as a leader in liver-directed oncology therapies through innovative product platforms and a growing commercialization footprint, with recent clinical and financial milestones underscoring its growth trajectory and expanding treatment adoption in the oncology community.
Company News
5 Stocks With Recent Price Strength Buoyed by a Strong August
Delcath Systems to Participate in Upcoming Investor Conferences
What Makes Delcath Systems, Inc. (DCTH) a Strong Momentum Stock: Buy Now?
Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why
Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 52.44%: Here's is How to Trade
Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why
Here's Why Delcath Systems, Inc. (DCTH) is a Great Momentum Stock to Buy
Does Delcath Systems (DCTH) Have the Potential to Rally 42.77% as Wall Street Analysts Expect?
Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcript
Delcath Systems Q2 Earnings Call Highlights
Delcath Systems, Inc. (DCTH) Tops Q2 Earnings and Revenue Estimates
Delcath Systems Reports Second Quarter 2026 Results and Business Highlights
Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference
Delcath Systems to Host Second Quarter 2026 Earnings Call
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
Is Delcath Systems Inc (DCTH) a Bargain After 3.8% Drop? GF Value Says Undervalued
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference